International Journal of Trichology

ABSTRACT
Year
: 2011  |  Volume : 3  |  Issue : 3  |  Page : 16-

Session G: Lunch Symposium Johnson & Johnson (Androgenetic Alopecia: Status and New Perspectives of Treatment)


 

Correspondence Address:




How to cite this article:
. Session G: Lunch Symposium Johnson & Johnson (Androgenetic Alopecia: Status and New Perspectives of Treatment).Int J Trichol 2011;3:16-16


How to cite this URL:
. Session G: Lunch Symposium Johnson & Johnson (Androgenetic Alopecia: Status and New Perspectives of Treatment). Int J Trichol [serial online] 2011 [cited 2019 Nov 21 ];3:16-16
Available from: http://www.ijtrichology.com/text.asp?2011/3/3/16/82156


Full Text

Androgenetic alopecia in women: Management options

Ulrike Blume-Peytavi

Department of Dermatology and Allergy, Clinical Research Center for Hair and Skin Science, Charité-Universitätsmedizin Berlin, Germany.

E-mail: ulrike.blume-peytavi@charite.de

Androgenetic alopecia (AGA) is the most common form of alopecia in men and women. Among women, approximately 6% to 38% experience some degree of frontal/frontoparietal hair loss. At present, the only clinically validated medication approved for increasing hair density in women with AGA is minoxidil topical solution (MTS), mostly 2% product but up to 5% in several countries. Recently a 5% minoxidil topical foam (MTF) twice daily was shown to be safe and effective in men using an aesthetically pleasing foam vehicle. We conducted a randomized, phase 3 study comparing the efficacy and safety of once-daily 5% MTF (50mg/day) versus twice-daily 2% MTS (40mg/day) in women with AGA. 113 women with AGA were randomized to 24 weeks of treatment with 5% MTF or 2% MTS. The primary efficacy parameter was change from baseline in nonvellus target area hair count (TAHC) at week 24. Secondary end points included change in nonvellus target area hair width (TAHW), overall efficacy by global photographic review (GPR), adverse events, and subjects' assessment of product aesthetics. After 24 weeks, women randomized to 5% MTF once daily showed non-inferior TAHC and TAHW and experienced greater, but non-significant, improvements in TAHC, TAHW, and overall efficacy by GPR than those randomized to 2% MTS twice daily. 5% MTF was significantly superior to 2% MTS in subjects' agreement with "the treatment does not interfere with styling my hair" (P=.001). Once-daily 5% MTF is non-inferior and as effective for stimulating hair growth as twice-daily 2% MTS in women with AGA and is associated with several aesthetic and practical advantages.

Minoxidil use in men

Rita Wanser

Johnson & Johnson Consumer Products Worldwide, Medical Affairs and Clinical Research, New Jersey, USA

E-mail: rwanser@its.jnj.com

Topical minoxidil is an evidenced based and regulatory approved agent for hair regrowth in men and women with androgenetic alopecia (AGA). It has been marketed for over 20 years, with a proven post marketing safety record. Extensive clinical programs were conducted to gain worldwide regulatory approvals. This presentation will explore an overview of minoxidil approval for use in AGA, and historical exploratory investigations utilizing different test methodologies, use in frontal pattern hair loss, and in combination with other active modalities for the management of AGA in men.